MEMEDPEarnings Analysis财报电话会Source pending来源待核by InvestLog AIInvestLog AI 整理
Event time: 事件时间：
Published: 文章发布：
MEDP earnings call: Full year 2026 total revenue is now expected in the range of $2.835 billion to $2.855 billion representing growth of 12% to 12.8% over 2025 total revenue of $2.53 billion Our 2026 EBITDA is now expected in the range of $638 million to $652 million representing growth of 14.4% to 16.9% compared to EBITDA of $557.7 million in 2025.Medpace Holdings, Inc. (MEDP) 电话会：我们预计2026年全年总营收区间为28.35亿至28.55亿美元，较2025年总营收25.3亿美元增长12%至12.8%；预计2026年EBITDA区间为6.38亿至6.52亿美元，较2025年的5.577亿美元EBITDA增长14.4%至16.9%。
Management remarks
Call period: 2026 Q3 · 2026-10-22
Guidance: Kevin Brady: Full year 2026 total revenue is now expected in the range of $2.835 billion to $2.855 billion representing growth of 12% to 12.8% over 2025 total revenue of $2.53 billion Our 2026 EBITDA is now expected in the range of $638 million to $652 million representing growth of 14.4% to 16.9% compared to EBITDA of $557.7 million in 2025.
Demand and orders: Kevin Brady: Net new business awards entering backlog in the third quarter increased 10.6% from the prior year to $873 million Net new business awards entering backlog over the last 12 months increased $3.02 billion representing a year over year increase of 23.9%.
Margins: Kevin Brady: Year to date EBITDA margin was 22.3%, compared to 21.8%.
Analyst Q&A
Analyst Christine Rains asked: The pass through revenue mix came in nicely below your prior 41% to 42% expectation for the second half. Is that range still the right expectation for 2H? Management Kevin Brady answered: Yeah, good question. I expect it to be somewhere around where we finished the third quarter. So kind of 40 to 40.5% based on our.
